AbSci AI

AbSci is a synthetic biology and AI company focused on using generative AI to design antibody and protein therapeutics. Rather than discovering drugs by screening vast libraries of existing molecules, AbSci's AI generates novel molecules with specified binding and functional properties — a fundamental shift from testing existing molecules toward designing new ones from scratch.

The Zero-Shot Protein Design platform uses generative AI trained on protein structure and function data to design novel antibodies with specified binding characteristics — telling the AI the target protein and desired binding affinity, and the AI generates candidate antibody sequences predicted to have those properties.

Drug-target interaction AI predicts how candidate molecules will interact with target proteins, estimating binding affinity and specificity without requiring synthesis and physical testing of each candidate. This computational prediction dramatically reduces the experimental cycle by screening in silico before committing to synthesis.

Cell line engineering AI optimises the biological production systems for manufacturing designed therapeutics — critical for scaling drug candidates from laboratory design to pharmaceutical manufacturing.

AbSci's published research has demonstrated zero-shot antibody design — generating functional antibody candidates for targets without prior experimental data for that specific target. Published in peer-reviewed journals including Nature, this research validates the scientific approach and positions AbSci in the generative AI for drug discovery field alongside Recursion and Insilico Medicine.

AbSci's business model combines pharmaceutical partnerships (licensing AI-designed drug candidates to pharma companies) with platform technology licensing to companies wanting AI-assisted drug design capabilities.